| Literature DB >> 31921780 |
Chioma Festus1, Sunday N Okafor2, Anthony C Ekennia3.
Abstract
A sequence of transition metal complexes of Mn(II), Co(II), Ni(II), and Cu(II) incorporating a novel pyrimidinyl based Schiff base ligand, 2-(4,6-dimethylpyrimidin-2-ylamino)naphthalene-1,4-dione (HL) and 2,2'-bipyridine has been synthesized and characterized using elemental, magnetic, conductance, infrared (FT-IR), nuclear magnetic resonance (1H- and 13C-NMR), electronic (UV-Vis), electrospray ionization mass spectrometry (ESI-MS), thermographic analysis (TGA), and molecular docking studies. The acquired results were consistent with the adoption of the chemical formula, [M(X)(L)(Y)]·nH2O (where M = Mn, Co, Ni, and Cu; L = Schiff base; X = 2,2'-bipy; Y = OAc; and n = 0,1) for the metallic complexes. HL ligand acts as a bidentate chelator and coordinates to metallic ion centre through carbonyl oxygen atom and deprotonated imide nitrogen. Similarly, 2,2'-bipy acts as a non-ionic bidentate chelator coordinating to metallic ion center via two nitrogen atoms. The mixed ligand complexes were appraised against pathogenic strains: S. aureus, P. aeruginosa, E. coli, B. cereus, P. mirabilis, K. oxytoca, A. niger, A. flevus, and R. Stolonifer. The antimicrobial studies gave moderate-good activity. Molecular docking studies on these compounds were done to indicate binding interactions between the compounds and adopted drug targets. Additionally, 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging activity of the compounds were determined at different concentrations. The antioxidant study showed good radical scavenging abilities.Entities:
Keywords: 2,2′-bipyridine; biological activities; molecular docking; naphthoquinone; pyrimidinyl
Year: 2019 PMID: 31921780 PMCID: PMC6933517 DOI: 10.3389/fchem.2019.00862
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.221
Scheme 1Synthetic Scheme of HL Schiff Base.
Figure 13D Structures of urate oxidase and human haematopoietic cell kinase. (A) 1WS3. (B) 2HCK.
Scheme 2Graphic degradation pathway of uric acid (1) to allantoin (3) through (2) (5-hydroxyisourate).
Scheme 3Fragmentation pattern of HL.
Thermal data presentation of HL and its complexes.
| HL | 195–220 | – | Melting point |
| [Mn(X)(L)(Y)] | 240–285 | 10.65 (10.79) | OCH3 + CO |
| [Co(X)(L)(Y)] | 290–340 | 18.50 (18.65) | N2O + OCH3 + CO |
| [Ni(X)(L)(Y)] | 240–310 | 11.0 (10.72) | CO + OCH3
|
| [Cu(X)(L)(Y)].H2O | 250–320 | 21.0 (21.04) | H2O +CO+2NO + OCH3
|
Antibacterial data of HL, 2,2′-bipy and their heteroleptic complexes.
| HL | 24.5 | 16.0 | 26.0 | 18.0 | 11.0 | 16.0 |
| Bipy | 15.5 | 12.0 | 26.0 | 8.5.0 | 17.0 | 19.0 |
| [Mn(X)(L)(Y)] | 31.0 | 18.7.0 | 23.0 | 16.0 | 20.0 | 28.0 |
| [Co(X)(L)(Y)] | 29.0 | 21.0 | 27.0 | 32.0 | 23.0 | 26.0 |
| [Ni(X)(L)(Y)] | 21.0 | 28.5.0 | R | R | 26.0 | 18.0 |
| [Cu(X)(L)(Y)].H2O | 29.0 | 22.0 | 24.0 | 31.0 | 34.0 | 27.0 |
| +Ciprofloxacin | 33.0 | 32.0 | 36.0 | 26.0 | 29.0 | 23.0 |
| -(CH3)2SO | R | R | R | R | R | R |
Antifungal data of HL, 2,2′-bipy and its heteroleptic complexes.
| HL | 23.0 | 29.0 | 27.0 |
| Bipy | 16.0 | 19.0 | 13.0 |
| [Mn(X)(L)(Y)] | 13.0 | 21.0 | – |
| [Co(X)(L)(Y)] | 23.0 | 21.0 | 25.0 |
| [Ni(X)(L)(Y)] | 13.0 | 23.0 | – |
| [Cu(X)(L)(Y)].H2O | – | – | – |
| + Fluconazole | 36.0 | 29.0 | 38.0 |
| -(CH3)2SO | – | – | – |
Antioxidant data of HL, 2,2′-bipy and their heteroleptic complexes.
| Blank | – | – |
| HL | Ic50 | 57.96 |
| Ic100 | 80.66 | |
| Ic200 | 83.23 | |
| Bipy | Ic50 | 74.76 |
| Ic100 | 76.23 | |
| Ic200 | 77.40 | |
| [Mn(X)(L)(Y)] | Ic50 | 86.96 |
| Ic100 | 58.53 | |
| Ic200 | 93.23 | |
| [Co(X)(L)(Y)] | Ic50 | 82.26 |
| Ic100 | 87.06 | |
| Ic200 | 93.83 | |
| [Ni(X)(L)(Y)] | Ic50 | 58.36 |
| Ic100 | 73.23 | |
| Ic200 | 75.76 | |
| [Cu(X)(L)(Y)].H2O | Ic50 | 82.26 |
| Ic100 | 84.26 | |
| Ic200 | 93.83 | |
| Standard ascorbic acid | Ic50 | 86.26 |
| Ic100 | 87.66 | |
| Ic200 | 88.67 |
Binding free energies ΔG (kcal mol−1) of compounds against drug targets.
| 1. | HL | −9.64 | −9.74 |
| 2. | [Mn(X)(L)(Y)] | −9.69 | −10.50 |
| 3. | [Co(X)(L)(Y)] | −11.43 | −9.53 |
| 4. | [Ni(X)(L)(Y)] | −12.94 | −8.87 |
| 5. | [Cu(X)(L)(Y)].H2O | −11.04 | −9.39 |
| 6. | Bipy | −7.30 | −7.79 |
| 7. | α-Tocopherol | −11.02 | ND |
| 8. | Quercetin | −14.08 | ND |
| 9. | Fluconazole | ND | −9.56 |
ND, Not determined.
Figure 2Authentication of docking protocol of (A) 2HCK and (B) 1WS3 (purple compound, co-crystalized ligand; green compound, docked ligand).
Figure 3Binding pose of compound 4 in the binding cavity of 2HCK (the green dotted lines signify H-bond; white dotted lines signify pi-H interaction).
Figure 42D representation of the binding interactions of compound 4 with amino acid residues of 2HCK.
Figure 5Binding pose of compound 2 in the binding cavity of 1WS3 (the green dotted lines signify H-bond; white dotted lines signify H-pi interaction).